Triple Threat-Triple Benefit: The Rise of GLP1-GCG-FGF21 Tritagonists in Tomorrow’s Metabolic Medicine . (2025). Diabzen, 3(3), 43-48. https://www.thediabzen.com/index.php/d/article/view/19